TITLE

Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo

AUTHOR(S)
Nader Shenouda; Mary Sakla; Leslie Newton; Cynthia Besch-Williford; Norman Greenberg; Ruth MacDonald; Dennis Lubahn
PUB. DATE
February 2007
SOURCE
Endocrine (1355008X);Feb2007, Vol. 31 Issue 1, p72
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BackgroundProstate cancer is an important public health problem. It is an excellent candidate disease for chemo-prevention because prostate cancer is typically slow growing and is usually diagnosed in elderly males. Pygeum africanum (Prunus africana or Rosaceae) is an African prune (plum) tree found in tropical Africa. An extract from the bark of Pygeum africanum has been used in Europe as a prevention and treatment of prostate disorders including benign prostatic hypertrophy (BPH). More recently in the USA, the phytotherapeutic preparations of Pygeum africanum and Saw palmetto have been marketed for prostate health including prostate cancer prevention and treatment.MethodsThe anti-cancer potential of Pygeum africanum has been tested both in vitro (PC-3 and LNCaP cells) and in?vivo (TRAMP mouse model).ResultsIn tissue culture, ethanolic extracts (30%) of Pygeum africanum inhibited the growth of PC-3 and LNCaP cells; induced apoptosis and altered cell kinetics; down regulated ERa and PKC-a protein, and demonstrated good binding ability to both mouse uterine estrogen receptors and LNCaP human androgen receptors. TRAMP mice fed Pygeum africanum showed a significant reduction (P = 0.034) in prostate cancer incidence (35%) compared to casein fed mice (62.5%).ConclusionPygeum africanum, which is widely used in Europe and USA for treatment of BPH, has a significant role in regulation of prostate cancer both in?vitro and in?vivo and therefore may be a useful supplement for people at high risk for developing prostate cancer.
ACCESSION #
26845296

 

Related Articles

  • Treatment Options in Hormone-Refractory Prostate Cancer: Current and Future Approaches. Harris, K.A.; Reese, D.M. // Drugs;Dec2001, Vol. 61 Issue 15, p2177 

    Prostate cancer is the second leading cause of cancer mortality among men in Western countries. The initial treatment of advanced prostate cancer is suppression of testicular androgen production by medical or surgical castration, but nearly all men with metastases will develop disease...

  • Chapter 8: When the Cancer Is Advanced. Barrett, David M. // Mayo Clinic on Prostate Health (2000);2000, p87 

    When prostate cancer spread outside the gland, curing the disease becomes difficult. In such cases, certain treatments can help slow its growth and even shrink the tumors. Chemotherapy, testicular surgery and hormone therapy are some of the ways to treat the cancer when it becomes advanced....

  • Age thresholds for aggressive PCa therapy are too low. Guttman, Cheryl // Urology Times;Nov2003, Vol. 31 Issue 11, p4 

    Reports on the findings of a study regarding the level of age-related thresholds for offering aggressive, potentially curative therapy to older man with high-grade, localized prostate cancer. Limitations of treatment decision models; Determination of efficacy outcomes; Presence of enrollment bias.

  • Prostate cancer drugs.  // Mayo Clinic Health Letter;Aug2003, Vol. 21 Issue 8, p4 

    Discusses factors to be considered when selecting treatment options for prostate cancer. Anatomy of the prostate; Chemotherapy; Radiation therapy; Side-effects of luteinizing hormone-releasing hormone agonist. INSET: Chemotherapy for prostate cancer..

  • Primary treatment of prostatic cancer.  // British Medical Journal;9/24/1977, Vol. 2 Issue 6090, p781 

    Focuses on the primary treatment of prostatic cancer in Great Britain. Recommendation on the use of radical prostatectomy for localized tumors; Uncertainties in the choice of primary treatments of prostatic cancer; Discussion on the difficulty of interpreting response to chemotherapeutic agents...

  • Preop chemotherapy plus hormones effective for PCa. Prescott, Lawrence M. // Urology Times;Sep99, Vol. 27 Issue 9, p6 

    Focuses on an approach to treating locally advanced prostate cancer reported by surgeons at M.D. Anderson Cancer Center in Houston, Texas. Combination of preoperative chemotherapy and hormonal therapy; Anti-tumor activity possessed by androgen ablation and chemotherapy; Clinical trials that...

  • Health Committee prostate cancer recommendations find favour with the Government.  // New Zealand Doctor;8/10/2011, p27 

    The article reports that the New Zealand government will probably quickly implement majority of the Health Committee's recommendations to improve the early detection and treatment of prostate cancer. According to the author, the Health Committee is also calling for the establishment of a quality...

  • Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen. Olson, William C.; Heston, Warren D. W.; Rajasekaran, Ayyappan K. // Reviews on Recent Clinical Trials;Sep2007, Vol. 2 Issue 3, p182 

    Prostate cancer is the most common non-cutaneous cancer of men in the United States and represents their second-leading cause of cancer-related death. Metastatic disease is largely resistant to conventional chemotherapies, and targeted therapies are urgently needed. Prostate-specific membrane...

  • In Vitro Effects Of Dutasteride And Finasteride On Prostate Cancer Cell Growth. Zaslau, Stanley; Perlmutter, Adam; Riggs, Dale; Jackson, Barbara; Kandzari, Stanley J. // Internet Journal of Urology;2008, Vol. 5 Issue 2, p7 

    Introduction: Dutasteride and finasteride are used to treat benign prostatic hyperplasia (BPH). The authors hypothesized that dutasteride and finasteride would affect the growth of prostate cells in vitro. Methods: Three prostate cancer cell lines (LnCaP, PC3, DU145) and one normal line...

  • Endocrine treatment of prostatic cancer. Williams, Gordon // Journal of the Royal Society of Medicine;Oct1985, Vol. 78 Issue 10, p797 

    The article comments on the endocrine treatment of prostatic cancer. The author said that early results of combination therapy aimed at total androgen ablation to block testicular androgen production seem to have significant advantages over single therapy. Some significant benefits beyond just...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics